aTyr Pharma announces research study with Stanford Medicine

aTyr Pharma has entered into a research agreement with Stanford Medicine. Michael Lim, M.D., Chair of the Department of Neurosurgery at Stanford Medicine, will serve as the principal investigator for the study. Dr. Lim’s research focuses on understanding the basic mechanisms of immunosuppression in glioblastoma multiforme. The research collaboration aims to explore the role of the Company’s novel function blocking antibodies against NRP2 in combination with chemotherapy to evaluate their role in reversing immune evasion in GBM. If preliminary studies are successful, the researchers plan to evaluate the NRP2 antibodies in combination with other immunomodulating agents, such as anti-PD-1, STING, or anti-CSF-1R, to address multiple targets of myeloid and T cell immunosuppression for the potential treatment of GBM.